REDWOOD CITY, Calif., Jan. 9, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that data from ongoing clinical trials of two novel anti-cancer stem cell therapeutics, both targeting the Notch cancer stem cell pathway and being evaluated in advanced pancreatic cancer, have been accepted for presentation at the upcoming 2014 Gastrointestinal Cancers Symposium being held January 16-18, 2014 at the Moscone West Convention Center in San Francisco, California. Data will be presented from OncoMed's Phase 1b clinical study of demcizumab and gemcitabine with and without nab-paclitaxel (Abraxane ®) and from the Phase 1b ALPINE ( Antibody therapy in first- Line Pancreatic cancer Investigating anti- Notch Efficacy and safety) clinical study of OMP-59R5 in combination with gemcitabine and nab-paclitaxel. Both clinical studies continue to enroll patients with first-line metastatic pancreatic cancer. The titles and timing of the poster presentations are:
Title: A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer. (Abstract #259; Poster Board B52) Presenting Author: Antonio Cubillo, M.D., START-Madrid Date and Time: Friday, January 17, 2014; 12:00pm - 2:00pm and 5:30pm - 7:00pm PT Title: Phase 1b of anti-cancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-Paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC) (Abstract #220; Poster Board A49) Presenting author: Eileen M. O'Reilly, M.D., Memorial Sloan-Kettering Cancer Center Date and Time: Friday, January 17, 2014; 12:00pm - 2:00pm and 5:30pm - 7:00pm PTAbout Cancer Stem Cells Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. OncoMed believes its product candidates are distinct from the current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer.